Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-005
- Development stage
- Preclinical
- Lead developer
- Theriva Biologics
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYN-005 is a **combination of two highly synergistic humanized monoclonal antibodies (hu1B7 and hu11E6)** developed to target and neutralize the pertussis toxin produced by *Bordetella pertussis*, the causative agent of pertussis (whooping cough). The antibodies are designed to inactivate this toxin, thereby reducing or preventing the life-threatening symptoms of the disease, especially in infants and newborns, for both prophylaxis and treatment. Antibiotics typically eliminate the bacteria but do not neutralize the pertussis toxin, making SYN-005 a targeted immunotherapeutic approach. SYN-005 has shown efficacy in non-human primate studies, both therapeutically and prophylactically, and has received Orphan Drug Designation from the FDA for the treatment of pertussis. The program is developed by Synthetic Biologics in collaboration with Intrexon and academic partners from the University of Texas at Austin[1][2][3][7][11].
- Brand names
- SYN-005SYN005SYN 005
- Other names
- SYN-005SYN005SYN 005
Beyond the preview
Go deeper on SYN-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN-005.